Daniele Tartini is a key account manager at SCHOTT Pharma. He has over 8 years of experience in the primary packaging and drug delivery industry, consulting pharma companies in choosing the right primary container and devices to de-risk the development of their combination products. Daniele supports pharmaceutical companies with their projects from early development, through clinical phases, and up to commercial launch and ramp-up. In this role, he’s helped pharma and biotech companies bring to market multiple vaccines and biologics in a pre-filled syringe and auto-injector presentation. Daniele holds degrees in Chemical Engineering from the Swiss Federal Institute of Technology in Zurich, and Business Administration from the Zurich University of Applied Sciences.

Dawn has been in the field of Data Management for more than 25 years, enjoying roles spanning entry level to department manager in academic research organizations as well as sponsor companies. In that time data collection has morphed from paper to EDC and the pace of life and work as sped up to keep pace with the innovations. Her breadth of experience has suited her to leading the eSource working group at Sanofi, working with an exciting and dynamic team to implement eSource supported data collection in the early development studies.

Ashwin Agarwal has served as Chief Financial Officer at Azura Ophthalmics since April 2021. Ashwin has over 25 years of financial, operations, investor relations, business strategy and leadership experience at both private and publicly traded companies spanning from early-stage to global, multi-billion organizations. Before joining, Azura Ophthalmics, Ashwin served as Vice President, Finance, Investor Relations, and Treasury at Evolus, Inc. During his tenure at Evolus, Ashwin strengthened the balance sheet by co-leading over $150M in public financing and driving organizational and operational efficiencies to accelerate revenue growth and improving cash flow. Prior to Evolus, Ashwin served as Vice President, Corporate Strategy for Alder Biopharmaceuticals, Inc. where he was responsible for investor relations, strategic financial planning, commercial market assessment and $250 million in public financing. Before Alder, Ashwin spent fifteen years at Allergan, Inc. in various finance and investor relations roles of increasing responsibility with his last role as Senior Director of Finance and Investor Relations. Ashwin began his career at KPMG where he spent three years in the auditing practice. He holds an MBA with an emphasis in Corporate Finance from the University of Southern California Marshall School of Business and a B.A. in Accounting from California State University, Fullerton.

Leah Broder is the Senior Vice President of Customer Strategy and Experience at Socially Determined, where she leads a team engaged across payer, provider, life sciences and partner organizations to identify and address social risks that drive meaningful change.

Leah is an experienced healthcare strategist, management consultant and public health professional with deep familiarity in navigating the development and execution of innovative product, data and digital health-enabled initiatives. Prior to joining Socially Determined, Leah served in leadership roles at The Advisory Board Company and Optum, overseeing client delivery and business expansion through digital transformation. Earlier in her career she worked at NYU Langone Medical Center during its electronic health record implementation and expansion, and also brings valuable insight on the payer perspective through roles at Aetna and WellNet Healthcare.

Leah holds a bachelor’s degree from the University of Michigan and a Master of Public Health from Columbia University with a focus on Health Policy and Management. She serves as a mentor for undergraduate students interested in healthcare through the University of Michigan.

Bryan is a seasoned professional in the medical device industry with over 20 years of experience spanning early-stage startups to global corporations. He has held diverse technical and leadership roles across product development and sustaining operations within the life science space. Bryan is currently with UCB focusing on the operational management of the UCB device portfolio.

As an epidemiologist at COPPER (Cancer Outcomes, Public Policy and Effectiveness Research) Center within the Department of General Medicine at the Yale School of Medicine, my research is focused on examining health outcomes and quality care for patients with cancer. I have a sub-focus to gain a better understanding of end-of-life care and the role of systemic anti-cancer therapy. Serving under the Smilow Chief Quality Officer I have researched this topic both within our institution, providing an evidence-based approach and critical statistical analysis to our quality improvement projects, and at the national level using secondary data analysis. I have worked extensively with the National Cancer Database (NCDB), SEER-Medicare data, Flatiron Health LLC US based real word cancer databases, and multi-site analysis of the Oncology Care Model (OCM) data. Prior to my work at COPPER, I was a member of the Global Health Leadership Institute (GHLI) team at Yale and conducted qualitative and quantitative data analysis of GHLI studies in countries including Ghana, Ethiopia and China.

Nancy Reilly, RN, MS, works as the Executive Director for the Rutgers Health - Clinical Trials Office. In this capacity, she oversees contract and budget negotiation, as well as feasibility assessment and coverage analysis for non-oncology clinical trials and is responsible for the development of streamlined and efficient workflows for non-oncology clinical research across the Rutgers Health enterprise. Ms. Reilly held prior roles in clinical research administration and also as a research nurse and research manager in HIV/Infectious Disease.

Dr. Jose M. Lagaron is a Full Professor, Founder, and Group Leader of the Novel Materials and Nanotechnology for Health Applications group at CSIC (Spanish National Research Council). He also serves as CEO and CSO of BioNanoPharma S.L. According to Scopus, Dr. Lagaron has authored 373 peer-reviewed publications, holds 78 patents, and has an h-index of 80—reflecting his significant impact in the fields of biopolymers and nanobiotechnology. He is a member of the editorial boards of several prominent scientific journals and currently serves as Vice-President of BIOVAL, the Bioregion of the Valencian Community in Spain. In addition to his academic and executive roles, Dr. Lagaron has founded multiple nanobiotech spin- offs, including Bioinicia S.L. and BioNanoPharma S.L., contributing to the translation of advanced technologies into commercial applications.

Jack is a Co-Founder of Altaviz and well-established in the medical device industry. Jack’s passion is leading smart people to creatively solve real-world problems with innovative solutions that yield effective, high-demand products and processes. Prior to founding Picocyl, Jack worked extensively with retina surgeons to deeply understand their objectives, identify their needs and translate those needs into current market-leading, state-of-the art, handheld surgical instruments. His fifteen successful years in motorsports and specialty vehicle design/development with the Toyota off road racing team and MillenWorks taught Jack to flourish at solving challenging problems in fast-paced, team-centric environments. He currently holds 51 US and 100 International patents.

Jack graduated from Cal Poly, San Luis Obispo with a BS in Mechanical Engineering. He is happily married with two great twenty-something children, active in the outdoors with a passion for hiking, lightweight backpacking and riding motorcycles.

Katie serves as the Director of Digital Enablement at GSK, driving the adoption of innovative digital health technologies within Clinical Operations. With a rich background spanning over 12 years and a Project Management Professional (PMP) certification, she expertly navigates Digital Health Strategy and Operations with Agile methodologies. As a published author and Digital Health Subject Matter Expert, Katie is a strategic owner behind GSK's award-winning Digital Health Platform, showcasing her leadership in transforming patient engagement through technology.

Since 2014, Tom Kelleher has been the CEO of Xylome Corporation where he engages in research and business development. Tom holds a doctorate in Industrial and Applied Microbiology from Rutgers University (1981) He is an SIMB Fellow and past president of the Pacific NW Chapter of the SIMB and past elected board member of the Puerto Rico Chapter of the Parenteral Drug Association. Between 2003 and 2014 at Amgen, Tom was Director in Global Process Engineering at Thousand Oaks and Puerto Rico sites. Between 1998 and 2003, Tom was the lead inventor of the current commercial process for Daptomycin (an antibiotic of last resort) that resulted in FDA approval of this new class of antibiotic for “super bugs”, including Vancomycin Resistant Enterococcus (VRE) and MRSA with sales exceeding $1-billion/year. Since 1980, Tom has held positions of increasing responsibility in process development and industrial microbiology at other biopharmaceutical companies, including ZymoGenetics/Novo Nordisk, Apha-1-antitrypsin at Chiron and Worthington Biochemicals. During his career, Tom was the owner representative or leadership team member for the construction, operation and successful FDA licensure of six GMP biopharma production plants.

Elliott Green is the Co-founder and CEO of Dandelion. His career has spanned a variety of executive roles within finance and health tech startups that are focused on payers, providers, life sciences, and healthcare data. Elliott was often the driving force behind complex, multi-institutional partnerships that would look to prove out new innovations.

Elliott’s career in US healthcare started at Oscar Health, where he expanded Oscar’s insurance business into California and Texas in response to the newly passed Affordable Care Act. He then coordinated Oscar’s expansion into 10 additional states, ultimately conceiving, contracting, and operationalizing the Oscar-Cleveland Clinic JV in Ohio.

After Oscar, Elliott joined TrialSpark (now Formation Bio) as the Head of Commercial Strategy and Partnerships. There he focused on provider partnerships and company strategy as TrialSpark looked to create a new patient experience, where clinical trials could be integrated into the everyday standard of care so patients could have greater access to innovative treatments. These efforts resulted in TrialSpark achieving acclaim as an industry disrupter on its way to a valuation of more than $1B. Elliott then joined Clarify Health as SVP and GM to drive improvements in the patient journey through data., before starting Dandelion.